Replication data for: Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals

Principal Investigator(s):  View help for Principal Investigator(s) Pierre Dubois; Laura Lasio

Version:  View help for Version V1

Name File Type Size Last Modified
  Matlab_Demand 10/12/2019 02:03:AM
  Matlab_optim_lambda 10/12/2019 02:03:AM
10_diff_in_diff.do text/plain 11.7 KB 10/11/2019 10:03:PM
14_elast_unc_margins.do text/plain 12.5 KB 10/11/2019 10:03:PM
15_lambda_prep.do text/plain 6.2 KB 10/11/2019 10:03:PM
19_lambda_confint.do text/plain 2.3 KB 10/11/2019 10:03:PM
1_FRA_data_prep.do text/plain 14 KB 10/11/2019 10:03:PM
20_constr_margins.do text/x-tex 3.1 KB 10/11/2019 10:03:PM
21_counterf_freepricing_prep.do text/plain 1.9 KB 10/11/2019 10:03:PM
24_counterf_ext_ref_prep.do text/plain 9.5 KB 10/11/2019 10:03:PM

Project Citation: 

Dubois, Pierre, and Lasio, Laura. Replication data for: Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals. Nashville, TN: American Economic Association [publisher], 2018. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-12. https://doi.org/10.3886/E112976V1

Project Description

Summary:  View help for Summary We develop a structural model to investigate the effects of pharmaceutical price regulation on demand and on manufacturers' price-setting behavior in France. We estimate price-cost margins in a regulated market with price constraints and infer whether these constraints are binding, exploiting cost restrictions across drugs, which come from observing the same drugs in potentially price-constrained markets (France) and in markets where prices are unregulated (US and Germany). Our counterfactual simulations suggest that price constraints generated modest savings for anti-ulcer drugs in 2003–2013 (2 percent of total expenses), relative to a free pricing scenario, and shifted consumption from generic to branded drugs.

Scope of Project

JEL Classification:  View help for JEL Classification
      C51 Model Construction and Estimation
      D24 Production; Cost; Capital; Capital, Total Factor, and Multifactor Productivity; Capacity
      I18 Health: Government Policy; Regulation; Public Health
      L13 Oligopoly and Other Imperfect Markets
      L51 Economics of Regulation
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics


Related Publications

Download this project

Published Versions

V1 [2019-10-12]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.